Company Profile
AbbVie Inc Stock Price, News & Analysis
- Ticker:
- ABBV
- Exchange:
- NYSE
- Sector:
- Biopharma, Immunotherapy, CNS
- Location:
- United States
Stock performance
243.87 USD (-0.95%)
Close
Last updated: August 6, 2026
381B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ABBV closed down 0.95% at $243.87. No new same-company headline was identified in the current news window.
Company overview
Business overview
AbbVie is a large biopharmaceutical company with major franchises in immunology, aesthetics, neuroscience, and oncology. Its identity has evolved from a single-product legacy into a broader diversified growth story.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NYSE, AbbVie has a global commercial footprint with meaningful exposure to both developed and international markets. It sits firmly in large-cap biopharma.
Business Model Characteristics
AbbVie combines mature cash flow with pipeline reinvestment and lifecycle management. Investors focus on immunology growth, aesthetic product performance, patent runoff, and the replacement cycle across its core portfolio.
Position Within the Biotechnology Landscape
AbbVie is a mature large-cap biotech-like pharma with a strong commercial base and ongoing catalyst sensitivity. It is not binary, but pipeline, label, and patent developments still matter for valuation.
Future catalysts
AbbVie’s key near-term catalysts are pivekimab sunirine’s BLA path, Rinvoq label-expansion opportunities, and continued Skyrizi momentum. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of AbbVie Inc (ABBV)?
AbbVie Inc (ABBV) most recently closed at 243.87 USD, a -0.95% move versus the previous session.
What is the market cap of AbbVie Inc (ABBV)?
AbbVie Inc currently has a market capitalization of 381B USD on BioPharmSignal.
What does AbbVie Inc do?
AbbVie is a large biopharmaceutical company with major franchises in immunology, aesthetics, neuroscience, and oncology. Its identity has evolved from a single-product legacy into a broader diversified growth story.
On which exchange is ABBV stock listed?
AbbVie Inc (ABBV) is associated with NYSE, United States, Biopharma, Immunotherapy, CNS.
What is pivekimab?
AbbVie’s key near-term catalysts are pivekimab sunirine’s BLA path, Rinvoq label-expansion opportunities, and continued Skyrizi momentum.
Which conditions is AbbVie Inc targeting with pivekimab?
AbbVie Inc is associated with oncology, immunology, neuroscience based on its company overview and current catalyst commentary.
How does AbbVie Inc describe recent progress with pivekimab?
AbbVie’s key near-term catalysts are pivekimab sunirine’s BLA path, Rinvoq label-expansion opportunities, and continued Skyrizi momentum.
What is AbbVie?
AbbVie is a large biopharmaceutical company with major franchises in immunology, aesthetics, neuroscience, and oncology.